MiNK Therapeutics, Inc. Common Stock (INKT)
Company finances score is on the low side — smart-money score is near the top of its range, while score for how it compares with the broader market is below the middle.
INKT scores higher than 60% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, MiNK Therapeutics, Inc. Common Stock (INKT) scores 46 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.91× 30-day average
- 52-week range
- 8.48 – 16.93
- Market cap
- $61.49M
- Earnings date
- 12 Nov 2026
- Volume
- 16,978
- Avg. volume (30d)
- 18,634
- Open
- 10.96
- Previous close
- 11.00
- Day's range (regular session)
- 10.68 – 10.96
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for INKT
- 5 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for INKT. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about INKT right now
MiNK Therapeutics, Inc. Common Stock (INKT) currently scores 46/100 on the Market Census six-factor composite, at the Average score level. INKT is -2.55% on the day and -13.83% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in INKT's data roughly balance out right now. INKT's strongest factor is insider trades at 90/100 — a very strong read on insider buying and selling. Insider filings currently lean toward buying on this name — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See INKT in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent INKT news
Latest headlines that name MiNK Therapeutics, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026Yahoo
- MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapyYahoo
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to INKT’s 46, all within 1 point.
Sorted by closeness to INKT’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.